INB-330

N/A

Report date: 2023/09/18 10:44:33

Base Information

Drug NameINB-330

Drug Alias NameINB-330

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsMyeloid cell surface antigen CD33 modulators

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIN8BIO Inc

China Registration ClassN/A

Develop Information

Active CompaniesIN8BIO Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic

Inactive IndicationsN/A

Other Information

ATC CodeN/A